Lederman gets $2.5M Gilead grant to study one-two punch

Gilead Sciences awards $2.5 million to CWRU AIDS Clinical Trials Unit

February 1, 2017: Gilead Sciences awarded CWRU School of Medicine’s Michael M. Lederman, MD to study HIV Reservoir Reduction with Interleukin-2 and monoclonal antibody treatments. IL-2 and certain monoclonal antibodies have been shown separately to reduce the presence of HIV, but have not been studied together as a potential cure.